Your prediction
Takeda Pharmaceutical Co Ltd Stock
Takeda Pharmaceutical Co Ltd gained 1.020% today.
Our community identified positive and negative aspects for Takeda Pharmaceutical Co Ltd stock for the coming years. 1 users see the criterium "Business model" as a plus for the Takeda Pharmaceutical Co Ltd stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Takeda Pharmaceutical Co Ltd in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
S********** s********
Cons
?
M***** P*******
?
B****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Takeda Pharmaceutical Co Ltd vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Takeda Pharmaceutical Co Ltd | 1.020% | 2.655% | 0.603% | 16.117% | 21.270% | 4.828% | 2.093% |
| Eisai Co Ltd | 1.220% | 3.503% | -1.927% | 6.470% | 7.765% | -47.316% | -52.209% |
| Chugai Pharmaceutical Co Ltd | 2.530% | 6.336% | -14.129% | 10.781% | 7.754% | 116.518% | 40.173% |
| Santen Pharmaceutical Corp Ltd. | 2.660% | 2.660% | 3.763% | 11.561% | 10.920% | 26.144% | -16.810% |
Comments
News
EQS-Adhoc: Takeda Pharmaceutical Company Limited: Takeda Announces Next Steps in its Transformation to Strengthen Competitiveness and Accelerate Future Growth Outlook
EQS-Adhoc: Takeda Pharmaceutical Company Limited: Takeda Announces Next Steps in its Transformation to Strengthen Competitiveness and Accelerate Future Growth Outlook
EQS-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2025 (IFRS)
EQS-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2025 (IFRS)